ProCE Banner Activity

KEYNOTE-024: Extended Survival Outcomes With First-line Pembrolizumab in PD-L1+ NSCLC

Slideset Download
Conference Coverage
Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.

Released: June 08, 2017

Expiration: June 07, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology